Literature DB >> 23937356

Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics.

Yung-Jue Bang1, Suayib Yalcin, Arnaud Roth, Simon Hitier, Mikhail Ter-Ovanesov, Chew-Wun Wu, John Zalcberg.   

Abstract

AIMS: A better understanding of treatment patterns and outcomes in different countries should improve the management of patients with gastric cancer globally. The REgistry of GAstric Cancer Treatment Evaluation (REGATE) study was established to evaluate variations in gastric cancer disease characteristics and treatment patterns in different parts of the world.
METHODS: REGATE was a prospective international registry enrolling patients with newly diagnosed gastric cancer at any stage of the disease.
RESULTS: A total of 10 299 patients (65% male; mean age 59 years) were recruited in 22 countries between 2004 and 2008. Tumor location at a proximal site was more common in Europe, Latin America and North Africa (approximately 20%) than in Asia-Pacific, where antral location predominated. Signet-ring cell histology predominated except in Europe, where adenocarcinoma was most prevalent. Stage I cancers were more frequent in Asia-Pacific (39%) versus other regions (6-18%), whereas stage IV cancers were more frequent outside Asia-Pacific. Surgery was planned for most patients, although in general fewer patients actually received surgery than originally planned. Adjuvant therapy and palliative care were generally used more frequently than originally planned. Overall, 15% of patients received no treatment (Asia-Pacific 8%; Indian subcontinent 25%).
CONCLUSIONS: These results provide a comprehensive database representative of gastric cancer disease characteristics and treatment patterns across the world.
© 2013 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  adjuvant chemotherapy; data collection; gastrectomy; palliative care; stomach neoplasms

Mesh:

Year:  2013        PMID: 23937356     DOI: 10.1111/ajco.12112

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  10 in total

1.  Pre-treatment Peripheral Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Gastric Cancer.

Authors:  Monika Magdy; Tarek Hussein; Ahmed Ezzat; Ahmed Gaballah
Journal:  J Gastrointest Cancer       Date:  2019-12

2.  The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally.

Authors:  Tessa Suzanne van Schooten; Sarah Derks; Andrés Cervantes; Tania Fleitas; Elena Jiménez-Martí; Fatima Carneiro; Ceu Figueiredo; Erika Ruiz; Maria Alsina; Cristina Molero; Marcelo Garrido; Arnoldo Riquelme; Carmelo Caballero; Eva Lezcano; Juan Manuel O'Connor; Federico Esteso; Judith Farrés; José Manuel Mas; Florian Lordick; Jeannette Vogt; Antonella Cardone; Charis Girvalaki
Journal:  BMC Cancer       Date:  2022-06-13       Impact factor: 4.638

Review 3.  Postoperative chemoradiotherapy vs. preoperative chemoradiotherapy for locally advanced (operable) gastric cancer: clarifying the role and technique of radiotherapy.

Authors:  Rebecca K S Wong; Raymond Jang; Gail Darling
Journal:  J Gastrointest Oncol       Date:  2015-02

4.  The economic burden of advanced gastric cancer in Taiwan.

Authors:  Jihyung Hong; Yiling Tsai; Diego Novick; Frank Chi-Huang Hsiao; Rebecca Cheng; Jen-Shi Chen
Journal:  BMC Health Serv Res       Date:  2017-09-16       Impact factor: 2.655

5.  Economic Burden of Gastric Cancer: A Case of Iran.

Authors:  Abed Eghdami; Rahim Ostovar; Abdosaleh Jafari; Andrew J Palmer; Najmeh Bordbar; Ramin Ravangard
Journal:  Cancer Control       Date:  2019 Jan-Dec       Impact factor: 3.302

6.  Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer.

Authors:  Jin Won Kim; Jong Gwang Kim; Byung Woog Kang; Ik-Joo Chung; Young Seon Hong; Tae-You Kim; Hong Suk Song; Kyung Hee Lee; Dae Young Zang; Yoon Ho Ko; Eun-Kee Song; Jin Ho Baek; Dong-Hoe Koo; So Yeon Oh; Hana Cho; Keun-Wook Lee
Journal:  Cancer Res Treat       Date:  2018-10-19       Impact factor: 4.679

7.  How are trial outcomes prioritised by stakeholders from different regions? Analysis of an international Delphi survey to develop a core outcome set in gastric cancer surgery.

Authors:  Bilal Alkhaffaf; Aleksandra Metryka; Jane M Blazeby; Anne-Marie Glenny; Paula R Williamson; Iain A Bruce
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

8.  Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.

Authors:  Gebra Cuyun Carter; Anna Kaltenboeck; Jasmina Ivanova; Astra M Liepa; Alexandra San Roman; Maria Koh; Narayan Rajan; Rebecca Cheng; Howard G Birnbaum; Jong Seok Kim; Yung-Jue Bang
Journal:  Cancer Res Treat       Date:  2016-09-12       Impact factor: 4.679

9.  Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer.

Authors:  David Gómez-Ulloa; Mayur Amonkar; Smita Kothari; Winson Y Cheung; Ian Chau; John R Zalcberg; Núria Lara Suriñach; Alfredo Falcone
Journal:  BMC Gastroenterol       Date:  2020-05-05       Impact factor: 3.067

10.  Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.

Authors:  Ian Chau; Dung T Le; Patrick A Ott; Beata Korytowsky; Hannah Le; T Kim Le; Ying Zhang; Teresa Sanchez; Gregory A Maglinte; Melissa Laurie; Pranav Abraham; Dhiren Patel; Tong Shangguan
Journal:  Gastric Cancer       Date:  2019-09-23       Impact factor: 7.370

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.